By: IPP Bureau
Last updated : December 30, 2025 9:56 am
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal Laboratories Limited has signed a Letter of Intent (LoI) with Switzerland-based Immuna Therapeutics GmbH for the exclusive India rights to next-generation CART cell therapies, including TriCAR-T platforms.
The proposed collaboration covers technology transfer, localization of manufacturing, clinical development, and commercialization in India. The initiative supports company's long-term strategy to expand into highvalue advanced therapies and cell and gene therapy platforms.
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation, driven by rising demand for advanced oncology treatments and improved access through localized manufacturing.
The partnership positions the company at the forefront of next-generation immuno-oncology in India while creating a scalable platform for future cell therapy programs.